Part 3 of this 3-part podcast series reviews FDA recommendations for translating data from in vitro, pharmacokinetic, clinical abuse potential, and postmarket studies into abuse-deterrent product labeling. <br /><a href="http://www.painmedicinenews.com/Monographs-White-Papers/Article/08-15/Abuse-Deterrent-Opioids-Product-Labeling/33256" target="_Blank">You can read more about this topic here</a>.

Part 3 of this 3-part podcast series reviews FDA recommendations for translating data from in vitro, pharmacokinetic, clinical abuse potential, and postmarket studies into abuse-deterrent product labeling. You can read more about this topic here.

Part 3 of this 3-part podcast series reviews FDA recommendations for translating data from in vitro, pharmacokinetic, clinical abuse potential, and postmarket studies into abuse-deterrent product labeling. <br><a href="http://www.painmedicinenews.com/Monographs-White-Papers/Article/08-15/Abuse-Deterrent-Opioids-Product-Labeling/33256" rel="noopener noreferrer">You can read more about this topic here</a>.

Abuse-Deterrent Opioids:
Product Labeling-Interview with Michael Brennan, MD

RSS feed : http://www.painmedicinenews.com

Share Abuse-Deterrent Opioids: Product Labeling-Interview with Michael Brennan, MD

Sign up to save your podcasts

Abuse-Deterrent Opioids: Product Labeling-Interview with Michael Brennan, MD

Abuse-Deterrent Opioids: Product Labeling-Interview with Michael Brennan, MD